A2B543

A2 Biotherapeutics Inc. · Phase 1 active Biologic

At a glance

Generic name	A2B543
Also known as	Tmod CAR T-cell Therapy
Sponsor	A2 Biotherapeutics Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

A2B543 CI brief — competitive landscape report
A2B543 updates RSS · CI watch RSS
A2 Biotherapeutics Inc. portfolio CI